<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Renal angiomyolipomas (AMLs): Management</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Renal angiomyolipomas (AMLs): Management</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Renal angiomyolipomas (AMLs): Management</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Vicente E Torres, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">York Pei, MD, FRCPC, FACP, FASN</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ronald D Perrone, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Deborah A Baumgarten, MD, MPH</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Eric N Taylor, MD, MSc, FASN</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 17, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H2407797066"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Angiomyolipomas (AMLs) are benign neoplasms occurring in the kidney and are composed of varying amounts of tissue resembling blood vessels, smooth muscles, and adipose. The vast majority of AMLs are benign but malignant transformation has been reported [<a href="#rid1">1-4</a>].</p><p>Renal AMLs may occur sporadically or in association with either tuberous sclerosis complex (TSC), sporadic lymphangioleiomyomatosis (LAM), or a combination (TSC-LAM). The management of AMLs depends upon factors such as the clinical presentation (eg, whether the patient is symptomatic with bleeding) and the size, number, and pathologic features of the lesions  (<a class="graphic graphic_algorithm graphicRef138463" href="/z/d/graphic/138463.html" rel="external">algorithm 1</a>). Some lesions also require monitoring over time.</p><p>This topic will discuss the management and prognosis of renal AMLs. Other related issues are discussed elsewhere:</p><p class="bulletIndent1"><span class="glyph">●</span>Epidemiology, pathogenesis, clinical manifestations, and diagnosis of renal AMLs (see  <a class="medical medical_review" href="/z/d/html/131412.html" rel="external">"Renal angiomyolipomas (AMLs): Epidemiology, pathogenesis, clinical manifestations, and diagnosis"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Renal manifestations of TSC (see  <a class="medical medical_review" href="/z/d/html/1684.html" rel="external">"Renal manifestations of tuberous sclerosis complex"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Renal AMLs associated with LAM (see  <a class="medical medical_review" href="/z/d/html/107651.html" rel="external">"Sporadic lymphangioleiomyomatosis: Clinical presentation and diagnostic evaluation", section on 'Renal angiomyolipomas'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A general overview of TSC-LAM (see  <a class="medical medical_review" href="/z/d/html/4329.html" rel="external">"Tuberous sclerosis complex associated lymphangioleiomyomatosis in adults"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An evaluation of incidental lesions of the kidney (see  <a class="medical medical_review" href="/z/d/html/116643.html" rel="external">"Evaluation of the incidental kidney lesion"</a>)</p><p></p><p class="headingAnchor" id="H50580413"><span class="h1">IDENTIFICATION AND MANAGEMENT OF ACTIVE BLEEDING</span></p><p class="headingAnchor" id="H1162893700"><span class="h2">Identification of active bleeding</span><span class="headingEndMark"> — </span>Hemorrhage from a sporadic renal AML is uncommon; in one large study, for example, 0.4 percent of sporadic AMLs bled [<a href="#rid5">5</a>]. Bleeding is more common in patients with tuberous sclerosis complex (TSC), as noted below. (See <a class="local">'Patients with known TSC or LAM'</a> below.)</p><p>Clinical and laboratory features suggestive of active bleeding from the AML include (see  <a class="medical medical_review" href="/z/d/html/131412.html" rel="external">"Renal angiomyolipomas (AMLs): Epidemiology, pathogenesis, clinical manifestations, and diagnosis", section on 'Clinical manifestations'</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Flank pain or tenderness</p><p class="bulletIndent1"><span class="glyph">●</span>Gross hematuria</p><p class="bulletIndent1"><span class="glyph">●</span>Anemia</p><p class="bulletIndent1"><span class="glyph">●</span>Acute deterioration in kidney function</p><p></p><p>All patients with AML who develop symptoms or signs suggestive of active bleeding should undergo prompt imaging with computed tomography (CT) or magnetic resonance imaging (MRI) to assess for hemorrhage from the AML.</p><p class="headingAnchor" id="H2125345786"><span class="h2">Management of active bleeding</span><span class="headingEndMark"> — </span>Bleeding from renal AMLs can be mild or catastrophic resulting in hemorrhagic shock, loss of function of the affected kidney, and death [<a href="#rid6">6,7</a>]. Patients with AML who develop active bleeding should receive resuscitative measures (if hemodynamically unstable) and, if feasible, undergo prompt angiography and selective artery embolization (SAE) to stop the bleeding. </p><p>Management of hemorrhagic shock from a bleeding AML is the same as for other causes of intraabdominal hemorrhage and is discussed at length elsewhere. (See  <a class="medical medical_review" href="/z/d/html/98976.html" rel="external">"Evaluation of and initial approach to the adult patient with undifferentiated hypotension and shock", section on 'When to suspect shock'</a> and  <a class="medical medical_review" href="/z/d/html/98976.html" rel="external">"Evaluation of and initial approach to the adult patient with undifferentiated hypotension and shock", section on 'Initial approach'</a> and  <a class="medical medical_review" href="/z/d/html/98976.html" rel="external">"Evaluation of and initial approach to the adult patient with undifferentiated hypotension and shock", section on 'Hemodynamically significant hemorrhage'</a>.)</p><p>Patients who cannot have SAE, or who continue to have life-threatening hemorrhage from a renal AML after an attempt at SAE, should undergo a partial or complete nephrectomy.</p><p>SAE is typically performed by interventional radiologists. However, depending upon institutional preference and availability of various services, this procedure may also be performed by urologists or general surgeons. At our institution, urologists are typically consulted and involved if the procedure will be performed by interventional radiologists. Such multidisciplinary consultation is beneficial in the event that SAE is unsuccessful and open surgical procedures (eg, partial or total nephrectomy) are needed to contain the bleeding. </p><p>SAE is an endovascular procedure by which the arteries supplying blood to a structure (eg, renal AML) are injected with an embolic agent with the goal of permanently occluding the blood supply to and inducing necrosis of the structure [<a href="#rid8">8</a>]. SAE is the preferred initial procedure in patients with acute life-threatening hemorrhage since it rapidly stabilizes the patient's condition and often eliminates the need for additional, more invasive procedures. SAE has resulted in reduction in the need for nephrectomy by 80 to 100 percent among patients with bleeding from renal AMLs [<a href="#rid8">8-10</a>]. Use of SAE is increasing due to its minimally invasive nature, improvements in safety (eg, with improved endovascular techniques and embolic materials), and growing procedural expertise. </p><p>SAE is generally tolerated well and is associated with fewer complications compared with open surgical procedures [<a href="#rid8">8</a>]. Complications that can occur from SAE include those related to the embolization, endovascular access, or the use of contrast. One of the most common complications occurring in nearly one-half of the patients undergoing SAE is postembolization syndrome (PES). PES is characterized by flank pain, which can be severe after embolization of a large AML, fever, vomiting, and leukocytosis; symptoms typically last one to three days [<a href="#rid11">11-13</a>]. </p><p>The risk of PES increases with the size of the mass being treated. PES is thought to result from a systemic inflammatory response to infarcted tissue. Although we do not use glucocorticoids to prevent PES, they have been used in some patients with varying degrees of success [<a href="#rid14">14</a>].</p><p>Other complications specific to embolization include inadvertent embolization of nearby vessels that can result in extensive renal infarction or infarction of parts of the spine, lower limbs, bowel, adrenal glands, or testicles. However, these complications are rare because of technical improvements over the last few decades. Long-term impact on kidney function is generally minimal but can vary depending upon the size of the infarct caused by embolization [<a href="#rid8">8</a>]. (See <a class="local">'Prognosis'</a> below.)</p><p>Possible complications related to the endovascular access include groin hematoma, arterial dissection, and thrombosis of the accessed arteries. Exposure to iodinated contrast can result in contrast-associated acute kidney injury or allergic reactions. </p><p class="headingAnchor" id="H3835323614"><span class="h1">MANAGEMENT OF SPORADIC AML</span></p><p class="headingAnchor" id="H3725856987"><span class="h2">Pretreatment assessment</span><span class="headingEndMark"> — </span>In patients diagnosed with sporadic AML, treatment is guided by the risk of malignant transformation and the risk of future bleeding  (<a class="graphic graphic_algorithm graphicRef138463" href="/z/d/graphic/138463.html" rel="external">algorithm 1</a>).</p><p class="headingAnchor" id="H3853202173"><span class="h3">Assess risk for malignant transformation</span><span class="headingEndMark"> — </span>The two major histologic variants of AMLs are classic and epithelioid. Among patients with sporadic AML, the epithelioid variant is uncommon. Classic variants, which do not undergo malignant transformation, are "fat-rich" by imaging. By contrast, epithelioid variants, which sometimes undergo malignant transformation, are "fat-poor" or "fat-invisible" by imaging. (See  <a class="medical medical_review" href="/z/d/html/131412.html" rel="external">"Renal angiomyolipomas (AMLs): Epidemiology, pathogenesis, clinical manifestations, and diagnosis", section on 'Histopathology'</a>.)</p><p>Thus, patients with a sporadic AML that is "fat-poor" or "fat-invisible" should generally undergo percutaneous core needle biopsy  (<a class="graphic graphic_algorithm graphicRef138463" href="/z/d/graphic/138463.html" rel="external">algorithm 1</a>). However, if imaging reveals intratumoral necrosis, intratumoral hemorrhage, lymphadenopathy, or suspected metastasis, then the likelihood of malignant transformation is higher. In such cases, biopsy of the lesion is usually not necessary; either the lesion is surgically excised, or the suspected metastases or abnormal lymph nodes are biopsied to help with staging and direct future therapy [<a href="#rid15">15</a>]. (See <a class="local">'Malignant AML or high risk for malignant transformation'</a> below.)</p><p>Biopsy findings that are consistent with a high risk of malignant transformation include: &gt;70 percent epithelioid cells; lymphovascular invasion; ≥2 mitotic figures per 10 high-power fields; atypical mitotic figures; and necrosis [<a href="#rid16">16,17</a>].  </p><p class="headingAnchor" id="H965006210"><span class="h3">Assess risk of bleeding</span><span class="headingEndMark"> — </span>As noted above, bleeding from renal AMLs can be mild or catastrophic resulting in hemorrhagic shock, loss of function of the affected kidney, and death [<a href="#rid6">6,7</a>]. The risk of bleeding increases with the size of the AML and the growth of the vasculature within it. We evaluate bleeding risk with imaging. </p><p>The initial imaging study (CT or MRI) performed for diagnosis of the AML can identify risk factors for bleeding. In addition, among patients who are selected for surveillance (with serial imaging), the rate of AML growth is associated with risk of bleeding.</p><p>Imaging and other features that are associated with a higher risk of bleeding include  (<a class="graphic graphic_algorithm graphicRef138463" href="/z/d/graphic/138463.html" rel="external">algorithm 1</a>) [<a href="#rid18">18-31</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>AML &gt;6 cm in diameter</strong> – In general, larger AMLs have a higher risk of bleeding than smaller AMLs [<a href="#rid18">18,20,21</a>]. In a systematic review of six studies including more than 1300 patients with AML, approximately 75 percent of hemorrhages occurred among patients with an AML &gt;6 cm in diameter [<a href="#rid20">20</a>]. Setting a threshold of &gt;4 cm for prophylactic embolization, which was the criteria used in the past, would be associated with a large number of unnecessary procedures.  </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Intralesional blood vessel or aneurysm &gt;5 mm in greatest width</strong> – Intralesional blood vessels or aneurysms can be difficult to visualize by imaging unless angiography is performed as part of the procedure [<a href="#rid22">22,23</a>] and, therefore, such information may not be available for every patient. We do <strong>not</strong> routinely obtain a dedicated angiographic study to look for intralesional aneurysms among patients who do not have evidence of active bleeding. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pregnancy or hormonal therapy</strong> – Estrogen and <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">progesterone</a> promote the growth of renal AMLs among pregnant patients and those treated with hormone replacement therapy [<a href="#rid24">24-30</a>]. In addition, estrogen and progesterone, coupled with cardiovascular adaptations in pregnancy, can increase the risk of hemorrhagic complications. (See  <a class="medical medical_review" href="/z/d/html/131412.html" rel="external">"Renal angiomyolipomas (AMLs): Epidemiology, pathogenesis, clinical manifestations, and diagnosis", section on 'Additional pathogenetic mechanisms in females'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>AML growth rate &gt;2.5 mm per year</strong> – A growth rate of this rapidity is associated with failure of active surveillance [<a href="#rid20">20,31-33</a>]. A growth rate ≤2.5 mm per year is considered low risk. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other potential risk factors</strong> – Other risk factors may include uncontrolled hypertension and anticoagulation or coagulopathy.</p><p></p><p class="headingAnchor" id="H1469706105"><span class="h2">Malignant AML or high risk for malignant transformation</span><span class="headingEndMark"> — </span>Patients who have been diagnosed as having epithelioid AML with malignant transformation require definitive management. Similarly, solitary AMLs deemed high risk for malignant transformation should also be treated.</p><p>Surgical management rather than selective artery embolization (SAE) is typically chosen for such patients, although angiographic treatment may be appropriate for patients with multiple comorbidities and/or reduced kidney function. A multidisciplinary approach to management is appropriate including, for example, urologists, nephrologists, oncologists, and pathologists. Surgical and angiographic treatment of such lesions is similar to that in patients with renal cell carcinoma; the details are presented elsewhere.</p><p>Patients with an epithelioid AML that has undergone malignant transformation also require an evaluation for distant metastases and may need systemic therapy [<a href="#rid34">34</a>]. This is presented separately. (See  <a class="medical medical_review" href="/z/d/html/14259.html" rel="external">"Clinical presentation, histopathology, diagnostic evaluation, and staging of soft tissue sarcoma"</a> and  <a class="medical medical_review" href="/z/d/html/7743.html" rel="external">"Overview of the initial treatment of metastatic soft tissue sarcoma"</a>.) </p><p>Patients who have undergone surgical removal of an epithelioid AML with high-risk histologic features should undergo serial imaging with MRI at six months, one year, and yearly for five years to assess for recurrence. </p><p class="headingAnchor" id="H173070222"><span class="h2">AML with low risk of malignant transformation</span><span class="headingEndMark"> — </span>In patients with sporadic AML at low risk for malignant transformation, the decision between intervention versus surveillance is based upon the size of the lesion (and other risk factors for bleeding) as well as other considerations (eg, patient's comorbidities, occupation)  (<a class="graphic graphic_algorithm graphicRef138463" href="/z/d/graphic/138463.html" rel="external">algorithm 1</a>). </p><p class="headingAnchor" id="H403035147"><span class="h3">Sporadic AML ≤6 cm</span><span class="headingEndMark"> — </span>Most patients with a sporadic AML ≤6 cm in diameter undergo surveillance (with imaging, to judge changes in the AML over time), rather than intervention with SAE or surgery. (See <a class="local">'Other patients (no compelling reason to intervene)'</a> below.)</p><p>However, in some patients, there is a compelling reason to intervene. (See <a class="local">'Compelling reasons to intervene'</a> below.)</p><p>The treatment of renal AMLs ≤6 cm in diameter is controversial because high-quality data are lacking.</p><p class="headingAnchor" id="H545256821"><span class="h4">Compelling reasons to intervene</span><span class="headingEndMark"> — </span>Most patients with sporadic AML ≤6 cm in diameter do not undergo intervention. However, the following are compelling reasons to treat the AML (with SAE, if feasible, rather than surgery)  (<a class="graphic graphic_algorithm graphicRef138463" href="/z/d/graphic/138463.html" rel="external">algorithm 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>AML growth rate greater than 2.5 mm per year. This rate of growth is associated with a higher risk of bleeding. A growth rate ≤2.5 mm per year is considered low risk. (See <a class="local">'Assess risk of bleeding'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>AML with a large intralesional aneurysm (&gt;5 mm diameter). Such patients are at a higher risk of bleeding from their AML. (See <a class="local">'Assess risk of bleeding'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>AML in a patient who could become pregnant or who is planning treatment with exogenous estrogen and/or <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">progesterone</a>. Such patients have a high risk of AML growth and bleeding during such states of hormonal excess and should be treated prior to becoming pregnant or receiving hormonal therapy. (See <a class="local">'Assess risk of bleeding'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Intolerable symptoms (eg, chronic pain) from their renal AML. Such patients could benefit with improvement in their symptoms upon treatment of the AML. (See  <a class="medical medical_review" href="/z/d/html/131412.html" rel="external">"Renal angiomyolipomas (AMLs): Epidemiology, pathogenesis, clinical manifestations, and diagnosis", section on 'Clinical manifestations'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Living in a setting with limited access to emergency services (eg, as would be needed for hemorrhage from an AML), or inability to undergo repeated imaging (for surveillance).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Intervention may be warranted in patients with certain high-risk occupations (eg, airline pilots).</p><p></p><p>Our approach is largely consistent with urology guidelines regarding management of AMLs from Canada (2020) [<a href="#rid21">21</a>] and Europe (2019) [<a href="#rid7">7</a>]. In addition, our approach is based upon findings of multiple small observational studies that examined outcomes of small to moderate AMLs over time and concluded that most smaller lesions remain stable without need for an intervention [<a href="#rid21">21,32,35-37</a>]. As an example, in a study of 447 patients with a renal AML (96 percent sporadic), 91 percent of patients were not symptomatic from their AML and the remainder either had pain (6.5 percent) or evidence of bleeding (2.5 percent) [<a href="#rid32">32</a>]. Approximately 6 percent of patients required intervention. At a median follow-up of 3.5 years, 91 percent of AMLs (most not treated) either did not grow or grew slowly (average growth rate 2 mm/year).  </p><p class="headingAnchor" id="H2660414464"><span class="h4">Other patients (no compelling reason to intervene)</span><span class="headingEndMark"> — </span>Patients with sporadic AML ≤6 cm in diameter and no compelling reason for intervention should undergo surveillance to assess for interval changes in the AML  (<a class="graphic graphic_algorithm graphicRef138463" href="/z/d/graphic/138463.html" rel="external">algorithm 1</a>). </p><p>There are no high-quality data to guide frequency or total duration of follow-up imaging among such patients. In our practice, we perform follow-up imaging using kidney ultrasound at six months after the initial diagnosis, and then yearly thereafter for up to five years (or longer if there is progressive growth of the AML). We use kidney ultrasound follow-up imaging rather than CT or MRI to minimize cost and exposure to ionizing radiation.</p><p>However, if the ultrasound suggests that growth has occurred, we obtain a CT or MRI (the same modality as was used to diagnose the AML originally) to better judge the rate of growth and other characteristics of the AML. The criteria for intervention rather than continued surveillance are the same criteria as noted above. (See <a class="local">'Compelling reasons to intervene'</a> above.)</p><p class="headingAnchor" id="H2305116618"><span class="h3">Sporadic AML &gt;6 cm</span><span class="headingEndMark"> — </span>Most patients with large sporadic AML (ie, &gt;6 cm in diameter) should undergo intervention (with SAE, if feasible, rather than surgery). </p><p>However, surveillance, rather than intervention, may be appropriate among a subset of such patients who have <strong>all</strong> of the following factors that are associated with a lower risk of bleeding  (<a class="graphic graphic_algorithm graphicRef138463" href="/z/d/graphic/138463.html" rel="external">algorithm 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Minimal vascularity of the AML, defined by the presence of small, stretched vessels that are few in number [<a href="#rid22">22</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patient is <strong>not</strong> anticoagulated or coagulopathic.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patient could <strong>not</strong> become pregnant and does not intend to take estrogen or <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">progesterone</a> therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Well-controlled blood pressure.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patient resides in a region where emergency services are available (in case of hemorrhage).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patient does <strong>not</strong> have a high-risk occupation (eg, airline pilot).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Documented stability of the lesion (ie, growth rate ≤2.5 mm annually) based upon previous serial imaging studies. If the lesion is already &gt;6 cm at the time of initial diagnosis, and the above factors associated with low risk are satisfied, it is reasonable to obtain serial imaging every four to six months over the ensuing year to judge stability. However, even among lesions that are growing slowly, intervention may be appropriate when they become substantially larger (decisions about intervention in such settings are typically made by a multidisciplinary team and after discussions with the patient).</p><p></p><p>The options for intervention include SAE or surgery (nephron-sparing surgery or total nephrectomy). The choice between the procedures depends upon local expertise, size and location of the lesion, and patient preference.</p><p>We prefer SAE as a first-line procedure because it is less invasive. However, SAE may not be technically feasible, in which case surgery is performed. When surgery is planned, we generally prefer nephron-sparing surgery rather than total nephrectomy. </p><p>There are no trials comparing SAE and surgery for management of AMLs. SAE can reduce AML size by approximately 25 to 80 percent [<a href="#rid8">8</a>], and thereby reduce or eliminate the likelihood of hemorrhage. However, AMLs can regrow following embolization and sequential embolization procedures may be required to ensure a successful outcome. In one study, for example, 71 patients with sporadic or tuberous sclerosis complex (TSC)-associated AMLs (median size 8.9 cm) were scheduled for SAE; six patients were unable to undergo SAE because of technical challenges [<a href="#rid38">38</a>]. Approximately 40 percent of the cohort needed one or more additional SAE procedures an average of two years after the initial procedure. The mean reduction in AML size was approximately 25 percent. During 10 years of follow-up, 10 patients were hospitalized with pain (three with retroperitoneal hemorrhage and seven with hematuria); only four patients eventually required surgery. Major complications of SAE leading to loss of the treated kidney occurred in two patients (one due to abscess and another due to thrombosis of the ipsilateral renal artery). Other, smaller studies have reported similar outcomes [<a href="#rid39">39-44</a>]. Details regarding the SAE procedure and other complications are discussed above. (See <a class="local">'Management of active bleeding'</a> above.)</p><p>If surgical resection of an AML is needed, several options are available. In general, nephron-sparing surgery, such as enucleation or partial nephrectomy, is preferred and usually effective among patients who have an exophytic or an otherwise well-demarcated tumor that is not located centrally (near the hilum). Recurrence rate is typically low after nephron-sparing surgery (approximately 4 to 15 percent) and additional surgery for these recurrent lesions is typically unnecessary (approximately 1 percent) [<a href="#rid7">7</a>].</p><p>Total nephrectomy is rarely used for management of a large renal AML. However, it may be indicated for patients who have a centrally located AML (near the hilum) because removal of such lesions with nephron-sparing surgery may lead to significant damage to the hilar vasculature or the ureter. </p><p class="headingAnchor" id="H3133501715"><span class="h1">PATIENTS WHO ARE PREGNANT OR ON HORMONE THERAPY</span><span class="headingEndMark"> — </span>Estrogen and <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">progesterone</a> promote the growth of renal AMLs among pregnant patients and those treated with these hormones [<a href="#rid24">24-30</a>]. In addition, estrogen coupled with cardiovascular adaptations in pregnancy increase the risk of hemorrhagic complications during pregnancy. (See  <a class="medical medical_review" href="/z/d/html/131412.html" rel="external">"Renal angiomyolipomas (AMLs): Epidemiology, pathogenesis, clinical manifestations, and diagnosis", section on 'Additional pathogenetic mechanisms in females'</a>.)</p><p>As noted above, treatment with exogenous estrogen or <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">progesterone</a> also may increase the risk for hemorrhage from a renal AML. Thus, patients with renal AML who could become pregnant or who need to be treated with hormonal therapy should generally undergo intervention on their AML. (See <a class="local">'Assess risk of bleeding'</a> above.)</p><p>However, individuals with an untreated renal AML occasionally become pregnant, and some pregnant patients have a renal AML discovered incidentally. Similarly, some patients with a renal AML initiate hormone therapy, and patients taking hormone therapy may be diagnosed with renal AML.</p><p>Our approach in these scenarios is as follows:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pregnant patients</strong> – In patients with a previously diagnosed but untreated renal AML who become pregnant, we perform a kidney ultrasound during the first and third trimesters to assess growth. In an individual who has a renal AML incidentally discovered during pregnancy, we perform a kidney ultrasound six months after the initial diagnosis. In general, we do not intervene on AMLs during pregnancy to avoid complications, for example, from hypotension and ionizing radiation. However, intervention is appropriate and feasible in patients who develop a life-threatening hemorrhage [<a href="#rid29">29,30</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients taking estrogen and/or </strong><a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">progesterone</a><strong> therapy</strong> – Patients with a known, untreated AML who initiate therapy with estrogen and/or progesterone, and patients taking such medications who are incidentally discovered to have a renal AML, should generally discontinue hormonal therapy. However, if hormonal therapy is necessary or cannot be avoided, then intervention is typically appropriate, particularly if the AML is larger than 3 to 4 cm in diameter. Repeat imaging may be necessary to reassess the size of the lesion. As in nonpregnant patients, our preferred approach to treat the AML is selective artery embolization (SAE), if feasible, rather than surgery. SAE is discussed in more detail above. (See <a class="local">'Management of active bleeding'</a> above.) </p><p></p><p class="headingAnchor" id="H1333343091"><span class="h1">PATIENTS WITH KNOWN TSC OR LAM</span><span class="headingEndMark"> — </span>Patients with tuberous sclerosis complex (TSC), sporadic lymphangioleiomyomatosis<strong> </strong>(LAM), and TSC-LAM generally have multiple AMLs at one time or over their lifetime. The management differs from that of sporadic AML because AMLs in TSC, LAM, and TSC-LAM are typically multicentric, grow more quickly, are more likely to hemorrhage, and are higher risk for malignant transformation [<a href="#rid32">32,45</a>]. In addition, such patients have a higher risk of chronic kidney disease, which may impact the choice of treatment modality. (See  <a class="medical medical_review" href="/z/d/html/1684.html" rel="external">"Renal manifestations of tuberous sclerosis complex", section on 'Renal cell carcinoma'</a> and  <a class="medical medical_review" href="/z/d/html/1684.html" rel="external">"Renal manifestations of tuberous sclerosis complex", section on 'Chronic kidney disease'</a> and  <a class="medical medical_review" href="/z/d/html/131412.html" rel="external">"Renal angiomyolipomas (AMLs): Epidemiology, pathogenesis, clinical manifestations, and diagnosis", section on 'Clinical manifestations'</a>.)</p><p>Our approach to renal AMLs among patients with TSC or LAM depends upon the number of AMLs, the rate of growth, the presence or absence of lesions with malignant transformation or high risk for malignant transformation, and the presence or absence of impaired kidney function: </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Referral to an expert center</strong> – If possible, patients with TSC should be managed by a team of clinicians with expertise in this disorder. Thus, referral to a <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.tscalliance.org%2Findividuals-families%2Ftsc-clinics%2F&amp;token=PJxPgiHFA3SgR3Ow9vACLmu77FhC9ZU3jx4bH98jDLOkhMVSVvyJ3KKyMA3ZAzBKiV7z0x0Jiv7GOPe6pP%2BTNq8AtSQsFLDSFqHlsS1NKKs%3D&amp;TOPIC_ID=90017" target="_blank">center of excellence</a> is appropriate.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Assess risk for malignant transformation</strong> – As noted above, AMLs that are fat poor or fat invisible should be assessed for risk of malignant transformation (by core needle biopsy or, if appropriate, surgical excision). (See <a class="local">'Assess risk for malignant transformation'</a> above.)</p><p></p><p class="bulletIndent1">Patients with lesions that are malignant or high risk for malignant transformation typically undergo surgical excision as well as further evaluation. Such patients are typically managed by a multidisciplinary team consisting of urologists, nephrologists, oncologists, and pathologists.  </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with a solitary AML</strong> – Patients with TSC or LAM who have a single renal AML are managed in the same way as patients with sporadic AML. (See <a class="local">'Management of sporadic AML'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with multiple renal AMLs</strong> – Among patients with TSC or LAM who have multiple AMLs, the treatment depends upon their number, size, rate of growth, presence or absence of impaired kidney function, and whether or not the patient is receiving a mammalian target of rapamycin (mTOR) inhibitor for a different manifestation of TSC. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>AMLs growingly rapidly (&gt;2.5 mm per year) </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Preserved kidney function (estimated glomerular filtration rate [eGFR] ≥60 mL/min/1.73 m<sup>2</sup>): In patients with multicentric AMLs, preserved kidney function, and two or more AMLs with a high growth rate, we initiate treatment with an mTOR inhibitor (typically <a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">everolimus</a>) rather than performing selective artery embolization (SAE) on multiple lesions, which may hasten kidney function decline [<a href="#rid46">46-50</a>]. </p><p></p><p class="bulletIndent3">In patients treated with <a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">everolimus</a> or <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a>, monitoring includes imaging every six months initially and then annually to judge the effect (or failure) of therapy, and routine laboratory monitoring for complications of the drug (including measurement of serum creatinine, urine albumin-to-creatinine ratio, electrolytes, phosphorous, complete blood count, and lipid profile). Adverse effects of mTOR inhibitors are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7329.html" rel="external">"Pharmacology of mammalian (mechanistic) target of rapamycin (mTOR) inhibitors", section on 'Adverse effects'</a>.) </p><p></p><p class="bulletIndent3">Rapid AML growth despite taking an mTOR inhibitor is rare. In such cases, the approach, which may include intervention (such as SAE) is determined after shared decision-making with the patient and the multidisciplinary team.</p><p></p><p class="bulletIndent3">If only one of the patient's AMLs is growing rapidly and is larger than 4 cm, then we typically choose SAE rather than treating with an mTOR inhibitor. </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Impaired kidney function (eGFR &lt;60 mL/min/1.73 m<sup>2</sup>): Treatment with an mTOR inhibitor is also appropriate for patients with impaired kidney function who have multiple, rapidly growing AMLs; such patients are usually initiated on an mTOR inhibitor before developing reduced kidney function. More frequent monitoring of serum creatinine and urine albumin excretion is required because acceleration of functional decline or a marked increase in albuminuria may occur as an adverse effect of the medication. The mTOR inhibitor should be discontinued if toxicity is suspected. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>AMLs that are stable or slow-growing (≤2.5 mm per year) – Patients with stable or slow growing AMLs are managed with surveillance (annual imaging with MRI or ultrasound). However, intervention (typically with SAE) is appropriate for lesions that are high risk for bleeding. The criteria are similar to those used in patients with sporadic AML. (See <a class="local">'Assess risk of bleeding'</a> above and <a class="local">'AML with low risk of malignant transformation'</a> above.) </p><p></p><p>Our approach is based upon evidence from several trials that <a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">everolimus</a> can reduce AML size and prevent AML growth [<a href="#rid46">46-50</a>]. In one trial, for example, 118 patients with TSC and at least one renal AML measuring &gt;3 cm were randomly assigned to everolimus (10 mg daily) or placebo [<a href="#rid46">46</a>]. At 38 weeks, a 30 percent or greater reduction in the size of all target AMLs occurred more commonly with everolimus (80 versus 3 percent), whereas progression of disease, defined as growth of one or more AMLs, development of new AMLs, or bleeding occurred less commonly (0 versus 23 percent). In those receiving everolimus who did not have a reduction in AML size, AMLs remained stable. </p><p>Patients from this trial were followed for approximately four years on open-label <a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">everolimus</a> [<a href="#rid47">47</a>]. Progression occurred in 14 percent of patients (most of whom had a dose reduction or dose interruption) and 7 percent had kidney function decline to an eGFR &lt;30 mL/min/1.73 m<sup>2</sup>; however, the majority of patients had stable kidney function.</p><p class="headingAnchor" id="H2284297729"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>The most important factor that impacts the long-term outcome of patients with renal AMLs is whether they have a sporadic AML or AMLs associated with tuberous sclerosis complex (TSC).</p><p>Sporadic AMLs are general singular and rarely require treatment. Most are discovered incidentally and typically remain stable without symptomatic bleeding. In general, the rate of bleeding requiring intervention, as well as the rate of elective intervention for high-risk AMLs, are low (eg, 0.1 and 1.4 percent, respectively, in one large series) [<a href="#rid32">32</a>]. Loss of kidney function from a sporadic renal AML is rare [<a href="#rid51">51</a>]. With the exception of patients who present with life-threatening hemorrhage, the impact of sporadic AMLs on mortality appears to be minimal, although this has not been systematically evaluated. </p><p>By contrast, TSC is associated with renal AMLs that are typically multicentric, grow more quickly, are more likely to hemorrhage, and are higher risk for malignant transformation [<a href="#rid32">32,45,51</a>]. Thus, they are more likely to require treatment and, consequently, result in treatment-associated nephron loss. In addition, patients with TSC often have chronic kidney disease due to factors unrelated to AMLs, such as chronic interstitial disease and secondary focal segmental glomerulosclerosis. Kidney disease, therefore, is one of the leading causes of death among patients with TSC [<a href="#rid52">52-54</a>]. (See  <a class="medical medical_review" href="/z/d/html/1684.html" rel="external">"Renal manifestations of tuberous sclerosis complex", section on 'Chronic kidney disease'</a> and  <a class="medical medical_review" href="/z/d/html/1684.html" rel="external">"Renal manifestations of tuberous sclerosis complex", section on 'End-stage kidney disease'</a> and  <a class="medical medical_review" href="/z/d/html/16902.html" rel="external">"Tuberous sclerosis complex: Management and prognosis", section on 'Prognosis'</a> and  <a class="medical medical_review" href="/z/d/html/4329.html" rel="external">"Tuberous sclerosis complex associated lymphangioleiomyomatosis in adults", section on 'Followup and prognosis'</a>.)</p><p class="headingAnchor" id="H211547290"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/110749.html" rel="external">"Society guideline links: Chronic kidney disease in adults"</a>.)</p><p class="headingAnchor" id="H4026263256"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Active bleeding from an AML</strong> – Patients with a renal angiomyolipoma (AML) who develop flank pain or tenderness or gross hematuria should undergo prompt imaging with computed tomography (CT) or magnetic resonance imaging (MRI) to assess for hemorrhage. Patients who develop active bleeding should receive resuscitative measures (if hemodynamically unstable) and, if feasible, undergo prompt angiography and selective artery embolization (SAE) to stop the bleeding. Patients who cannot have SAE, or who continue to have life-threatening hemorrhage from a renal AML after an attempt at SAE, should undergo a partial or complete nephrectomy. (See <a class="local">'Identification and management of active bleeding'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pretreatment assessment of sporadic AML</strong> – In patients diagnosed with sporadic AML, the treatment is guided by the risk of malignant transformation and the risk of future bleeding  (<a class="graphic graphic_algorithm graphicRef138463" href="/z/d/graphic/138463.html" rel="external">algorithm 1</a>) (see <a class="local">'Pretreatment assessment'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Assess risk of malignant transformation – AMLs that are (by imaging) "fat rich" do not undergo malignant transformation. By contrast, "fat-poor" or "fat-invisible" AMLs (ie, epithelioid AMLs) should generally undergo percutaneous core needle biopsy to assess risk for malignant transformation. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Assess risk of bleeding – Imaging and other features that are associated with a higher risk of bleeding include: AML diameter &gt;6 cm; intralesional blood vessel or aneurysm &gt;5 mm at greatest width; AML growth rate &gt;2.5 mm per year; anticoagulation or coagulopathy; and uncontrolled hypertension.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management of sporadic AML</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Malignant AML or AML at high risk for malignant transformation – Patients who have been diagnosed as having an epithelioid AML with malignant transformation, and patients with an AML deemed high risk for malignant transformation should also be treated. Surgical management rather than SAE is typically chosen for such patients, although angiographic treatment may be appropriate for patients with multiple comorbidities and/or reduced kidney function. (See <a class="local">'Malignant AML or high risk for malignant transformation'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Other sporadic AMLs – In patients with a sporadic AML at low risk for malignant transformation, the decision between intervention versus surveillance is based upon the size of the lesion (and other risk factors for bleeding) as well as other considerations (eg, patient's comorbidities, occupation)  (<a class="graphic graphic_algorithm graphicRef138463" href="/z/d/graphic/138463.html" rel="external">algorithm 1</a>). (See <a class="local">'AML with low risk of malignant transformation'</a> above.)</p><p></p><p class="bulletIndent2">Most patients with sporadic AML ≤6 cm in diameter undergo surveillance (with imaging, to judge changes in the AML over time). However, in patients with sporadic AML ≤6 cm in diameter and one or more of the following criteria, we suggest intervention (with SAE, if feasible) rather than surveillance (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>) (see <a class="local">'Sporadic AML ≤6 cm'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Annual AML growth rate faster than 2.5 mm per year </p><p class="bulletIndent3"><span class="glyph">-</span>AML with a large intralesional aneurysm (&gt;5 mm diameter)</p><p class="bulletIndent3"><span class="glyph">-</span>In someone who could become pregnant (or planning exogenous estrogen or <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">progesterone</a> therapy) </p><p class="bulletIndent3"><span class="glyph">-</span>Intolerable symptoms (eg, chronic pain) from their renal AML </p><p class="bulletIndent3"><span class="glyph">-</span>Residence in a setting with limited access to emergency services </p><p class="bulletIndent3"><span class="glyph">-</span>In someone with a high-risk occupation (eg, airline pilots)</p><p></p><p class="bulletIndent2">In most patients with a large sporadic AML (ie, &gt;6 cm in diameter), we suggest intervention (with SAE, if feasible), rather than surveillance (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). However, surveillance, rather than intervention, may be appropriate among a subset of such patients who have <strong>all</strong> of the following factors that are associated with a lower risk of bleeding (see <a class="local">'Sporadic AML &gt;6 cm'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Minimal vascularity of the AML</p><p class="bulletIndent3"><span class="glyph">-</span><strong>Not</strong> anticoagulated or coagulopathic</p><p class="bulletIndent3"><span class="glyph">-</span>Could <strong>not</strong> become pregnant and does <strong>not</strong> intend to take estrogen or <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">progesterone</a> therapy</p><p class="bulletIndent3"><span class="glyph">-</span>Well-controlled blood pressure</p><p class="bulletIndent3"><span class="glyph">-</span>Residing in a region where emergency services are readily available</p><p class="bulletIndent3"><span class="glyph">-</span><strong>No</strong> high-risk occupation (eg, airline pilot)</p><p class="bulletIndent3"><span class="glyph">-</span>Documented stability of the lesion (ie, growth rate ≤2.5 mm annually) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tuberous sclerosis complex (TSC) and sporadic lymphangioleiomyomatosis (LAM)</strong> – Patients with TSC, LAM, and TSC-LAM generally have multiple AMLs at one time or over their lifetime. If possible, all such patients should be managed by a team of clinicians with expertise at a <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.tscalliance.org%2Findividuals-families%2Ftsc-clinics%2F&amp;token=PJxPgiHFA3SgR3Ow9vACLmu77FhC9ZU3jx4bH98jDLOkhMVSVvyJ3KKyMA3ZAzBKiV7z0x0Jiv7GOPe6pP%2BTNq8AtSQsFLDSFqHlsS1NKKs%3D&amp;TOPIC_ID=90017" target="_blank">center of excellence</a>. (See <a class="local">'Patients with known TSC or LAM'</a> above.)`</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Solitary AML – Patients with TSC or LAM who have a single renal AML are managed in the same way as patients with sporadic AML. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Multiple AMLs that are stable or slow-growing (&lt;2.5 mm per year) – Patients with stable or slow growing AMLs are managed with surveillance (ie, annual imaging with MRI or ultrasound). However, intervention (typically with SAE) is appropriate for lesions that are high risk for bleeding. The criteria are similar to those used in patients with sporadic AML. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Multiple AMLs growingly rapidly (&gt;2.5 mm per year) – In patients with two or more AMLs with a high growth rate, we initiate treatment with a mammalian target of rapamycin (mTOR) inhibitor (typically <a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">everolimus</a>) rather than no treatment or performing SAE on multiple lesions (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>).</p><p></p><p class="headingAnchor" id="H204451412"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The editorial staff at UpToDate would like to acknowledge William M Bennett, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Ferry JA, Malt RA, Young RH. Renal angiomyolipoma with sarcomatous transformation and pulmonary metastases. Am J Surg Pathol 1991; 15:1083.</a></li><li><a class="nounderline abstract_t">Matute Martinez CF, Hamdan A, Sierra David JG, Kolli S. Sporadic, classic-type renal angiomyolipoma with renal vein and inferior vena cava extension: an incidental case. BMJ Case Rep 2021; 14.</a></li><li><a class="nounderline abstract_t">Parekh V, Shen D. Invasive Renal Angiomyolipoma With Cytologic Atypia. Int J Surg Pathol 2017; 25:177.</a></li><li><a class="nounderline abstract_t">Sato K, Ueda Y, Tachibana H, et al. Malignant epithelioid angiomyolipoma of the kidney in a patient with tuberous sclerosis: an autopsy case report with p53 gene mutation analysis. Pathol Res Pract 2008; 204:771.</a></li><li><a class="nounderline abstract_t">Fittschen A, Wendlik I, Oeztuerk S, et al. Prevalence of sporadic renal angiomyolipoma: a retrospective analysis of 61,389 in- and out-patients. Abdom Imaging 2014; 39:1009.</a></li><li><a class="nounderline abstract_t">Xu XF, Hu XH, Zuo QM, et al. A scoring system based on clinical features for the prediction of sporadic renal angiomyolipoma rupture and hemorrhage. Medicine (Baltimore) 2020; 99:e20167.</a></li><li><a class="nounderline abstract_t">Fernández-Pello S, Hora M, Kuusk T, et al. Management of Sporadic Renal Angiomyolipomas: A Systematic Review of Available Evidence to Guide Recommendations from the European Association of Urology Renal Cell Carcinoma Guidelines Panel. Eur Urol Oncol 2020; 3:57.</a></li><li><a class="nounderline abstract_t">Muller A, Rouvière O. Renal artery embolization-indications, technical approaches and outcomes. Nat Rev Nephrol 2015; 11:288.</a></li><li><a class="nounderline abstract_t">Chang YH, Wang LJ, Chuang CK, et al. The efficacy and outcomes of urgent superselective transcatheter arterial embolization of patients with ruptured renal angiomyolipomas. J Trauma 2007; 62:1487.</a></li><li><a class="nounderline abstract_t">Chan CK, Yu S, Yip S, Lee P. The efficacy, safety and durability of selective renal arterial embolization in treating symptomatic and asymptomatic renal angiomyolipoma. Urology 2011; 77:642.</a></li><li><a class="nounderline abstract_t">Vora A, Brodsky R, Nolan J, et al. Incidence of postembolization syndrome after complete renal angioinfarction: a single-institution experience over four years. Scand J Urol 2014; 48:245.</a></li><li><a class="nounderline abstract_t">Lee S, Park HS, Hyun D, et al. Radiologic and clinical results of transarterial ethanol embolization for renal angiomyolipoma. Eur Radiol 2021; 31:6568.</a></li><li><a class="nounderline abstract_t">Lin L, Li X, Guan H, et al. Renal function, complications, and outcomes of a reduction in tumor size after transarterial embolization for renal angiomyolipomas: a meta-analysis. J Int Med Res 2019; 47:1417.</a></li><li><a class="nounderline abstract_t">Bissler JJ, Racadio J, Donnelly LF, Johnson ND. Reduction of postembolization syndrome after ablation of renal angiomyolipoma. Am J Kidney Dis 2002; 39:966.</a></li><li><a class="nounderline abstract_t">Sooriakumaran P, Gibbs P, Coughlin G, et al. Angiomyolipomata: challenges, solutions, and future prospects based on over 100 cases treated. BJU Int 2010; 105:101.</a></li><li><a class="nounderline abstract_t">Brimo F, Robinson B, Guo C, et al. Renal epithelioid angiomyolipoma with atypia: a series of 40 cases with emphasis on clinicopathologic prognostic indicators of malignancy. Am J Surg Pathol 2010; 34:715.</a></li><li><a class="nounderline abstract_t">Nese N, Martignoni G, Fletcher CD, et al. Pure epithelioid PEComas (so-called epithelioid angiomyolipoma) of the kidney: A clinicopathologic study of 41 cases: detailed assessment of morphology and risk stratification. Am J Surg Pathol 2011; 35:161.</a></li><li><a class="nounderline abstract_t">Yamakado K, Tanaka N, Nakagawa T, et al. Renal angiomyolipoma: relationships between tumor size, aneurysm formation, and rupture. Radiology 2002; 225:78.</a></li><li><a class="nounderline abstract_t">De Luca S, Terrone C, Rossetti SR. Management of renal angiomyolipoma: a report of 53 cases. BJU Int 1999; 83:215.</a></li><li><a class="nounderline abstract_t">Ryan JW, Farrelly C, Geoghegan T. What Are the Indications for Prophylactic Embolization of Renal Angiomyolipomas? A Review of the Current Evidence in the Literature. Can Assoc Radiol J 2018; 69:236.</a></li><li><a class="nounderline abstract_t">Guo Y, Kapoor A, Cheon P, et al. Canadian Urological Association best practice report: Diagnosis and management of sporadic angiomyolipomas. Can Urol Assoc J 2020; 14:E527.</a></li><li><a class="nounderline abstract_t">Rimon U, Duvdevani M, Garniek A, et al. Large renal angiomyolipomas: digital subtraction angiographic grading and presentation with bleeding. Clin Radiol 2006; 61:520.</a></li><li><a class="nounderline abstract_t">Champagnac J, Melodelima C, Martinelli T, et al. Microaneurysms in renal angiomyolipomas: Can clinical and computed tomography features predict their presence and size? Diagn Interv Imaging 2016; 97:321.</a></li><li><a class="nounderline abstract_t">Lewis EL, Palmer JM. Renal angiomyolipoma and massive retroperitoneal hemorrhage during pregnancy. West J Med 1985; 143:675.</a></li><li><a class="nounderline abstract_t">Petrikovsky BM, Vintzileos AM, Cassidy SB, Egan JF. Tuberous sclerosis in pregnancy. Am J Perinatol 1990; 7:133.</a></li><li><a class="nounderline abstract_t">Raft J, Lalot JM, Meistelman C, Longrois D. [Renal angiomyolipoma rupture during pregnancy]. Gynecol Obstet Fertil 2006; 34:917.</a></li><li><a class="nounderline abstract_t">Zapardiel I, Delafuente-Valero J, Bajo-Arenas JM. Renal angiomyolipoma during pregnancy: review of the literature. Gynecol Obstet Invest 2011; 72:217.</a></li><li><a class="nounderline abstract_t">Gould Rothberg BE, Grooms MC, Dharnidharka VR. Rapid growth of a kidney angiomyolipoma after initiation of oral contraceptive therapy. Obstet Gynecol 2006; 108:734.</a></li><li><a class="nounderline abstract_t">Ugwumba FO, Nnakenyi EF, Okafor OC, et al. Renal Angiomyolipoma in Pregnancy: Surgical Management with Fetal Preservation - Approach in a Developing Setting. Clin Pract 2016; 6:893.</a></li><li><a class="nounderline abstract_t">Zhao Y, Yang Z, Xu W, et al. Management of renal tumors during pregnancy: case reports. BMC Nephrol 2021; 22:127.</a></li><li><a class="nounderline abstract_t">Cai Y, Li H, Zhang Y. Re: Jaimin R. Bhatt, Patrick O. Richard, Nicole S. Kim, et al. Natural History of Renal Angiomyolipoma (AML): Most Patients with Large AMLs &gt;4cm Can Be Offered Active Surveillance as an Initial Management Strategy. Eur Urol 2016;70:85-90. Eur Urol 2017; 71:e141.</a></li><li><a class="nounderline abstract_t">Bhatt JR, Richard PO, Kim NS, et al. Natural History of Renal Angiomyolipoma (AML): Most Patients with Large AMLs &gt;4cm Can Be Offered Active Surveillance as an Initial Management Strategy. Eur Urol 2016; 70:85.</a></li><li><a class="nounderline abstract_t">Vaggers S, Rice P, Somani BK, et al. Evidence-based protocol-led management of renal angiomyolipoma: A review of literature. Turk J Urol 2021; 47:S9.</a></li><li><a class="nounderline abstract_t">Lei JH, Liu LR, Wei Q, et al. A Four-Year Follow-up Study of Renal Epithelioid Angiomyolipoma: A Multi-Center Experience and Literature Review. Sci Rep 2015; 5:10030.</a></li><li><a class="nounderline abstract_t">Swärd J, Henrikson O, Lyrdal D, et al. Renal angiomyolipoma-patient characteristics and treatment with focus on active surveillance. Scand J Urol 2020; 54:141.</a></li><li><a class="nounderline abstract_t">Chan KE, Chedgy E, Bent CL, Turner KJ. Surveillance imaging for sporadic renal angiomyolipoma less than 40 mm: lessons learnt and recommendations from the experience of a large district general hospital. Ann R Coll Surg Engl 2018; 100:480.</a></li><li><a class="nounderline abstract_t">Nason GJ, Morris J, Bhatt JR, et al. Natural History of Renal Angiomyolipoma Favors Surveillance as an Initial Approach. Eur Urol Focus 2021; 7:582.</a></li><li><a class="nounderline abstract_t">Anis O, Rimon U, Ramon J, et al. Selective Arterial Embolization for Large or Symptomatic Renal Angiomyolipoma: 10 Years of Follow-up. Urology 2020; 135:82.</a></li><li><a class="nounderline abstract_t">Ewalt DH, Diamond N, Rees C, et al. Long-term outcome of transcatheter embolization of renal angiomyolipomas due to tuberous sclerosis complex. J Urol 2005; 174:1764.</a></li><li><a class="nounderline abstract_t">Williams JM, Racadio JM, Johnson ND, et al. Embolization of renal angiomyolipomata in patients with tuberous sclerosis complex. Am J Kidney Dis 2006; 47:95.</a></li><li><a class="nounderline abstract_t">Lenton J, Kessel D, Watkinson AF. Embolization of renal angiomyolipoma: immediate complications and long-term outcomes. Clin Radiol 2008; 63:864.</a></li><li><a class="nounderline abstract_t">Lee SY, Hsu HH, Chen YC, et al. Embolization of renal angiomyolipomas: short-term and long-term outcomes, complications, and tumor shrinkage. Cardiovasc Intervent Radiol 2009; 32:1171.</a></li><li><a class="nounderline abstract_t">Villalta JD, Sorensen MD, Durack JC, et al. Selective arterial embolization of angiomyolipomas: a comparison of smaller and larger embolic agents. J Urol 2011; 186:921.</a></li><li><a class="nounderline abstract_t">Planché O, Correas JM, Mader B, et al. Prophylactic embolization of renal angiomyolipomas: evaluation of therapeutic response using CT 3D volume calculation and density histograms. J Vasc Interv Radiol 2011; 22:1388.</a></li><li><a class="nounderline abstract_t">Ariceta G, Buj MJ, Furlano M, et al. Recommendations for the management of renal involvement in the tuberous sclerosis complex. Nefrologia (Engl Ed) 2020; 40:142.</a></li><li><a class="nounderline abstract_t">Bissler JJ, Kingswood JC, Radzikowska E, et al. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 2013; 381:817.</a></li><li><a class="nounderline abstract_t">Bissler JJ, Kingswood JC, Radzikowska E, et al. Everolimus long-term use in patients with tuberous sclerosis complex: Four-year update of the EXIST-2 study. PLoS One 2017; 12:e0180939.</a></li><li><a class="nounderline abstract_t">Franz DN, Belousova E, Sparagana S, et al. Long-Term Use of Everolimus in Patients with Tuberous Sclerosis Complex: Final Results from the EXIST-1 Study. PLoS One 2016; 11:e0158476.</a></li><li><a class="nounderline abstract_t">Bissler JJ, Budde K, Sauter M, et al. Effect of everolimus on renal function in patients with tuberous sclerosis complex: evidence from EXIST-1 and EXIST-2. Nephrol Dial Transplant 2019; 34:1000.</a></li><li><a class="nounderline abstract_t">Bissler JJ, Nonomura N, Budde K, et al. Angiomyolipoma rebound tumor growth after discontinuation of everolimus in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis. PLoS One 2018; 13:e0201005.</a></li><li><a class="nounderline abstract_t">Nelson CP, Sanda MG. Contemporary diagnosis and management of renal angiomyolipoma. J Urol 2002; 168:1315.</a></li><li><a class="nounderline abstract_t">Zak S, Mokhallati N, Su W, et al. Lymphangioleiomyomatosis Mortality in Patients with Tuberous Sclerosis Complex. Ann Am Thorac Soc 2019; 16:509.</a></li><li><a class="nounderline abstract_t">Amin S, Lux A, Calder N, et al. Causes of mortality in individuals with tuberous sclerosis complex. Dev Med Child Neurol 2017; 59:612.</a></li><li><a class="nounderline abstract_t">Shepherd CW, Gomez MR, Lie JT, Crowson CS. Causes of death in patients with tuberous sclerosis. Mayo Clin Proc 1991; 66:792.</a></li></ol></div><div id="topicVersionRevision">Topic 90017 Version 23.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1928559" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Renal angiomyolipoma with sarcomatous transformation and pulmonary metastases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33727284" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Sporadic, classic-type renal angiomyolipoma with renal vein and inferior vena cava extension: an incidental case.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27596442" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Invasive Renal Angiomyolipoma With Cytologic Atypia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18547741" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Malignant epithelioid angiomyolipoma of the kidney in a patient with tuberous sclerosis: an autopsy case report with p53 gene mutation analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24705668" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Prevalence of sporadic renal angiomyolipoma: a retrospective analysis of 61,389 in- and out-patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32443333" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : A scoring system based on clinical features for the prediction of sporadic renal angiomyolipoma rupture and hemorrhage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31171501" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Management of Sporadic Renal Angiomyolipomas: A Systematic Review of Available Evidence to Guide Recommendations from the European Association of Urology Renal Cell Carcinoma Guidelines Panel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25536394" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Renal artery embolization-indications, technical approaches and outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17563671" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : The efficacy and outcomes of urgent superselective transcatheter arterial embolization of patients with ruptured renal angiomyolipomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21131030" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : The efficacy, safety and durability of selective renal arterial embolization in treating symptomatic and asymptomatic renal angiomyolipoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24215333" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Incidence of postembolization syndrome after complete renal angioinfarction: a single-institution experience over four years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33733687" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Radiologic and clinical results of transarterial ethanol embolization for renal angiomyolipoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30898061" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Renal function, complications, and outcomes of a reduction in tumor size after transarterial embolization for renal angiomyolipomas: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11979340" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Reduction of postembolization syndrome after ablation of renal angiomyolipoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19493268" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Angiomyolipomata: challenges, solutions, and future prospects based on over 100 cases treated.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20410812" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Renal epithelioid angiomyolipoma with atypia: a series of 40 cases with emphasis on clinicopathologic prognostic indicators of malignancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21263237" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Pure epithelioid PEComas (so-called epithelioid angiomyolipoma) of the kidney: A clinicopathologic study of 41 cases: detailed assessment of morphology and risk stratification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12354988" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Renal angiomyolipoma: relationships between tumor size, aneurysm formation, and rupture.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10233482" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Management of renal angiomyolipoma: a report of 53 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29804911" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : What Are the Indications for Prophylactic Embolization of Renal Angiomyolipomas? A Review of the Current Evidence in the Literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33213697" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Canadian Urological Association best practice report: Diagnosis and management of sporadic angiomyolipomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16713423" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Large renal angiomyolipomas: digital subtraction angiographic grading and presentation with bleeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26780886" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Microaneurysms in renal angiomyolipomas: Can clinical and computed tomography features predict their presence and size?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4082575" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Renal angiomyolipoma and massive retroperitoneal hemorrhage during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2184812" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Tuberous sclerosis in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16996772" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : [Renal angiomyolipoma rupture during pregnancy].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21876331" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Renal angiomyolipoma during pregnancy: review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17018483" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Rapid growth of a kidney angiomyolipoma after initiation of oral contraceptive therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28176962" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Renal Angiomyolipoma in Pregnancy: Surgical Management with Fetal Preservation - Approach in a Developing Setting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33836679" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Management of renal tumors during pregnancy: case reports.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27769715" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Re: Jaimin R. Bhatt, Patrick O. Richard, Nicole S. Kim, et al. Natural History of Renal Angiomyolipoma (AML): Most Patients with Large AMLs&gt;4cm Can Be Offered Active Surveillance as an Initial Management Strategy. Eur Urol 2016;70:85-90.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26873836" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Natural History of Renal Angiomyolipoma (AML): Most Patients with Large AMLs&gt;4cm Can Be Offered Active Surveillance as an Initial Management Strategy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32966208" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Evidence-based protocol-led management of renal angiomyolipoma: A review of literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25939249" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : A Four-Year Follow-up Study of Renal Epithelioid Angiomyolipoma: A Multi-Center Experience and Literature Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31971051" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Renal angiomyolipoma-patient characteristics and treatment with focus on active surveillance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29658337" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Surveillance imaging for sporadic renal angiomyolipoma less than 40 mm: lessons learnt and recommendations from the experience of a large district general hospital.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32636160" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Natural History of Renal Angiomyolipoma Favors Surveillance as an Initial Approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31618658" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Selective Arterial Embolization for Large or Symptomatic Renal Angiomyolipoma: 10 Years of Follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16217279" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Long-term outcome of transcatheter embolization of renal angiomyolipomas due to tuberous sclerosis complex.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16377390" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Embolization of renal angiomyolipomata in patients with tuberous sclerosis complex.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18625350" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Embolization of renal angiomyolipoma: immediate complications and long-term outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19572171" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Embolization of renal angiomyolipomas: short-term and long-term outcomes, complications, and tumor shrinkage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21791345" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Selective arterial embolization of angiomyolipomas: a comparison of smaller and larger embolic agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21757371" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Prophylactic embolization of renal angiomyolipomas: evaluation of therapeutic response using CT 3D volume calculation and density histograms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31722796" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Recommendations for the management of renal involvement in the tuberous sclerosis complex.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23312829" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28792952" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Everolimus long-term use in patients with tuberous sclerosis complex: Four-year update of the EXIST-2 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27351628" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Long-Term Use of Everolimus in Patients with Tuberous Sclerosis Complex: Final Results from the EXIST-1 Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30053159" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Effect of everolimus on renal function in patients with tuberous sclerosis complex: evidence from EXIST-1 and EXIST-2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30192751" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Angiomyolipoma rebound tumor growth after discontinuation of everolimus in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12352384" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Contemporary diagnosis and management of renal angiomyolipoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30571922" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Lymphangioleiomyomatosis Mortality in Patients with Tuberous Sclerosis Complex.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27935023" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Causes of mortality in individuals with tuberous sclerosis complex.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1861550" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Causes of death in patients with tuberous sclerosis.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
